Expired activity
Please go to the PowerPak homepage and select a course.

Expanding Horizons in Immuno-Oncology: Health System Pharmacists' Perspectives

Provided by The University of Tennessee College of Pharmacy, in cooperation with ASiM.
Supported by an educational grant from Bristol-Myers Squibb Company.


Immunotherapies incorporate novel mechanisms of action, response patterns, and safety profiles, which distinguishes them from cytotoxic agents and even targeted therapies. As immunotherapies continue to demonstrate favorable responses in clinical trials, thus leading to US Food and Drug Administration approval, the use of these therapies will continue to increase. Due to the uniqueness of immunotherapies, pharmacists need to know and understand the differences between cytotoxic and targeted agents versus therapies that elicit a true immune response and strategies for managing patients who may present with immunotherapy-related issues and concerns. This webcast archive features interactive case-based discussions and will review the pharmacology and clinical use of immunotherapies. Specifically, it will address the response and immune-related adverse events associated with these treatments, their benefits, and methods for optimally managing patients being treated with these novel therapies.


The goal of this activity is to provide health system pharmacists with the information necessary to understand the evolving science, clinical pharmacy, response assessment, adverse event management, and formulary issues regarding immunotherapies in oncology.


This activity is designed for health-system pharmacists. No prerequisites required.


The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:

  • DIFFERENTIATE the mechanisms of active immunotherapies from that of targeted and cytotoxic therapies.
  • EVALUATE clinical trial data and uses of PD-1 and CTLA-4 inhibitors in malignancies.
  • RECOGNIZE unique disease response patterns associated with immunotherapy treatment.
  • IDENTIFY strategies to recognize and manage adverse events related to immunotherapies.


acpeThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based program will provide a statement for 1.5 contact hours of credit (0.15 CEUs) and will be available at the completion of the activity. Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the educational activity; 3) completing the self-assessment instrument  with a score of at least 70%. CE credit will be submitted to the NABP CE Monitor. UAN:  0064-0000-15-206-H01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days.  It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

NABP e-PROFILE ID NUMBER: Your CE credits will also be submitted electronically to NABP. Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service. To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their date and month of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

Please allow up to 30 days for your credit to appear on CPE Monitor.

Type of Activity: Application
Published: April 1, 2016
Expires: April 1, 2017

Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 90 minutes


Participants must complete the activity as described above in the Credit Designation Statement. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of CE credit will be made available immediately. Click on View Certificate and print the CE statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test.


As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:


Val R. Adams, PharmD, FCCP, BCOP (Chair)
Associate Professor 
Pharmacy Practice and Science Department
College of Pharmacy
University of Kentucky
Lexington, Kentucky 
Dr Adams reports serving on an advisory board for Teva.

David Frame, PharmD
Clinical Assistant Professor of Pharmacy and Clinical Pharmacist
College of Pharmacy
U-M Health System
Ann Arbor, Michigan 
Dr Frame reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

R. Donald Harvey, PharmD, FCCP, BCOP
Associate Professor, Hematology/Medical Oncology
Director, Phase 1 Clinical Trials Section
Winship Cancer Institute of Emory University
Atlanta, Georgia 
Dr Harvey reports serving as a consultant for Amgen Inc/Onyx Pharmaceuticals (for oprozomib development); and serving on an advisory board for Baxter (for intravenous immunoglobulin [IVIG]), Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company, Ltd (for ixazomib). Dr Harvey's spouse reports receiving grants/research support from Baxalta and Novo Nordisk; and serving as a consultant for Baxalta and Biogen Idec.


In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the reader of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.


The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.


A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at gfarr@utasip.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.


The following is an interactive case simulation designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CPE post-test, and evaluation. All 3 sections must be completed to receive CPE credit. A statement of credit will be available online immediately following successful completion of the activity.


Please ensure the computer you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible.
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5



Activity Overview and Goals
R. Donald Harvey, PharmD, FCCP, BCOP

Pharmacology and Clinical Use of Immunotherapies
R. Donald Harvey, PharmD, FCCP, BCOP

Pharmacists' Role and the Interpretation of Gray Areas of Immunotherapy:
Case Studies
R. Donald Harvey, PharmD, FCCP, BCOP, and Val R. Adams, PharmD, FCCP, BCOP

Question and Answer Session
R. Donald Harvey, PharmD, FCCP, BCOP, and Val R. Adams, PharmD, FCCP, BCOP

Postassessment and Evaluation

What you are about to see is a previously recorded live webcast. Please note that only "home study" credit will be awarded for participating in this archived presentation.

No "live" credits are available.